In this regard, the V617F mutation in JAK2, leading to gain in function, is a recurring feature of myeloproliferative disorders, and patients harboring this mutation have been shown to have a longer duration of disease and are also at increased risk for fibrosis. This evidence concerns the gene JAK2 and myeloproliferative disorder.